147 related articles for article (PubMed ID: 30516678)
1. 68Ga-DOTA-TOC PET/CT of von Hippel-Lindau Disease.
Liberini V; Nicolotti DG; Maccario M; Finessi M; Deandreis D
Clin Nucl Med; 2019 Feb; 44(2):125-126. PubMed ID: 30516678
[TBL] [Abstract][Full Text] [Related]
2. 18F-FDG and 68Ga-DOTATATE PET/CT in von Hippel-Lindau Disease-Associated Retinal Hemangioblastoma.
Papadakis GZ; Millo C; Jassel IS; Bagci U; Sadowski SM; Karantanas AH; Patronas NJ
Clin Nucl Med; 2017 Mar; 42(3):189-190. PubMed ID: 28033220
[TBL] [Abstract][Full Text] [Related]
3. 68Ga-DOTA-NOC PET/CT detects somatostatin receptors expression in von hippel-lindau cerebellar disease.
Ambrosini V; Campana D; Allegri V; Opocher G; Fanti S
Clin Nucl Med; 2011 Jan; 36(1):64-5. PubMed ID: 21157217
[TBL] [Abstract][Full Text] [Related]
4. 68Ga DOTATATE PET/CT Versus 18F-FDG PET/CT for Detecting Intramedullary Hemangioblastoma in a Patient With Von Hippel-Lindau Disease.
Banezhad F; Kiamanesh Z; Emami F; Sadeghi R
Clin Nucl Med; 2019 Jun; 44(6):e385-e387. PubMed ID: 30985433
[TBL] [Abstract][Full Text] [Related]
5. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.
Gabriel M; Oberauer A; Dobrozemsky G; Decristoforo C; Putzer D; Kendler D; Uprimny C; Kovacs P; Bale R; Virgolini IJ
J Nucl Med; 2009 Sep; 50(9):1427-34. PubMed ID: 19690033
[TBL] [Abstract][Full Text] [Related]
6. Potential role of (68)Ga-DOTATOC PET/CT in screening for pancreatic neuroendocrine tumour in patients with von Hippel-Lindau disease.
Prasad V; Tiling N; Denecke T; Brenner W; Plöckinger U
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2014-20. PubMed ID: 27293206
[TBL] [Abstract][Full Text] [Related]
7. Al18F-NOTA-Octreotide PET/CT and 18F-FDG PET/CT for Detecting Cerebellar Hemangioblastoma in a Patient With Von Hippel-Lindau Disease.
Hou G; Cheng X; Chi Y; Wang X; Zheng R
Clin Nucl Med; 2024 Mar; 49(3):289-291. PubMed ID: 38306383
[TBL] [Abstract][Full Text] [Related]
8. Kidney Tumor in a von Hippel-Lindau (VHL) Patient With Intensely Increased Activity on 68Ga-DOTA-TATE PET/CT.
Papadakis GZ; Millo C; Sadowski SM; Bagci U; Patronas NJ
Clin Nucl Med; 2016 Dec; 41(12):970-971. PubMed ID: 27749408
[TBL] [Abstract][Full Text] [Related]
9. Different manifestations detected with 68Ga-DOTATOC PET/CT in patients with Von Hippel-Lindau disease: A case report.
Meneret P; Girard A; Pagenault M; Riffaud L; Palard-Novello X
Nuklearmedizin; 2020 Aug; 59(4):332-334. PubMed ID: 32193881
[No Abstract] [Full Text] [Related]
10. Epididymal Cystadenomas in von Hippel-Lindau Disease Showing Increased Activity on 68Ga DOTATATE PET/CT.
Papadakis GZ; Millo C; Sadowski SM; Bagci U; Patronas NJ
Clin Nucl Med; 2016 Oct; 41(10):781-2. PubMed ID: 27454594
[TBL] [Abstract][Full Text] [Related]
11. Incidental Detection of Viral Conjunctivitis on 68Ga-DOTANOC PET/CT in a Patient Suspected With Von Hippel-Lindau Syndrome.
Mathur Y; Krishnaraju VS; Singh H; Kumar R; Dutta P
Clin Nucl Med; 2022 May; 47(5):e408-e410. PubMed ID: 35195580
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1.
Morgat C; Vélayoudom-Céphise FL; Schwartz P; Guyot M; Gaye D; Vimont D; Schulz J; Mazère J; Nunes ML; Smith D; Hindié E; Fernandez P; Tabarin A
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1258-66. PubMed ID: 26819103
[TBL] [Abstract][Full Text] [Related]
13. 68 Ga-DOTANOC PET/CT in 2 Siblings With Von Hippel-Lindau Disease.
G B P; Damle NA; Reddy K R; Tandon N; Naranje P; Kandasamy D; Subudhi K
Clin Nucl Med; 2024 Jun; 49(6):e266-e268. PubMed ID: 38537203
[TBL] [Abstract][Full Text] [Related]
14. Endolymphatic Sac Tumor Showing Increased Activity on 68Ga DOTATATE PET/CT.
Papadakis GZ; Millo C; Sadowski SM; Bagci U; Patronas NJ
Clin Nucl Med; 2016 Oct; 41(10):783-4. PubMed ID: 27454593
[TBL] [Abstract][Full Text] [Related]
15. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.
Nilica B; Waitz D; Stevanovic V; Uprimny C; Kendler D; Buxbaum S; Warwitz B; Gerardo L; Henninger B; Virgolini I; Rodrigues M
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1585-92. PubMed ID: 26922350
[TBL] [Abstract][Full Text] [Related]
16. The utility of
Shell J; Tirosh A; Millo C; Sadowski SM; Assadipour Y; Green P; Patel D; Nilubol N; Kebebew E
Eur J Radiol; 2019 Mar; 112():130-135. PubMed ID: 30777201
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin receptor expression on von Hippel-Lindau-associated hemangioblastomas offers novel therapeutic target.
Sizdahkhani S; Feldman MJ; Piazza MG; Ksendzovsky A; Edwards NA; Ray-Chaudhury A; Maric D; Merrill MJ; Pacak K; Zhuang Z; Chittiboina P
Sci Rep; 2017 Jan; 7():40822. PubMed ID: 28094316
[TBL] [Abstract][Full Text] [Related]
18. Von Hippel-Lindau syndrome: demonstration of entire disease spectrum with (68)Ga-DOTANOC PET-CT.
Sharma P; Dhull VS; Bal C; Malhotra A; Kumar R
Korean J Radiol; 2014; 15(1):169-72. PubMed ID: 24497809
[TBL] [Abstract][Full Text] [Related]
19. Robust labeling and comparative preclinical characterization of DOTA-TOC and DOTA-TATE.
Velikyan I; Xu H; Nair M; Hall H
Nucl Med Biol; 2012 Jul; 39(5):628-39. PubMed ID: 22336375
[TBL] [Abstract][Full Text] [Related]
20. Ga-68 Somatostatin Receptor PET/CT in von Hippel-Lindau Disease.
Oh JR; Kulkarni H; Carreras C; Schalch G; Min JJ; Baum RP
Nucl Med Mol Imaging; 2012 Jun; 46(2):129-33. PubMed ID: 24900047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]